Kiniksa Pharmaceuticals Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

76.30$ +0.7% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Kiniksa Pharmaceuticals Ltd (KNSA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 896 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet KNSA
Line item	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	56	–	–	–	47	225	365	347	322	346	308	282	255	226	271	384	349	311	279	253	233	231	211	460	460	443	484	483	526	520	542	555	581	599	661	712	764	825	896
Current Assets	56	56	–	–	47	222	364	342	314	335	296	268	242	213	264	378	333	276	245	218	196	199	180	242	243	232	246	256	276	271	301	311	332	356	420	476	527	594	669
Cash	56	-56	–	–	46	221	286	338	307	327	287	259	47	106	123	86	114	120	168	190	122	63	94	176	123	81	113	118	108	141	99	97	184	157	192	175	166	190	176
Cash & Short-Term Investments	–	56	–	–	46	221	359	338	307	327	287	259	233	204	252	364	323	264	226	200	182	146	138	201	191	187	185	201	206	214	219	224	244	268	308	352	414	468	526
Receivables	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.2	2.6	3.2	4.0	29	7.8	11	20	7.4	25	3.0	21	16	20	25	42	40	32	52	16	23	23
Inventory	–	–	–	–	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	2.2	6.4	5.6	3.7	13	20	15	22	23	24	26	31	27	35	29	26	22	48	41	55	73	71
Property, Plant & Equipment	0.1	–	–	–	0.1	0.1	0.4	2.4	6.4	9.5	8.9	8.6	8.3	7.4	6.5	4.6	4.1	3.8	3.4	3.2	2.8	2.5	2.2	2.0	1.7	1.4	1.1	14	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	20	20	20	19	19	19	19	18	18	18	18	17	17	17	17	16	16	16	16	15	15	15
Total Liabilities	2.3	–	–	–	137	19	23	28	43	40	33	30	29	20	21	26	38	40	43	39	48	65	57	76	64	53	73	78	87	88	107	118	142	142	166	177	196	220	242
Current Liabilities	2.3	–	–	–	17	19	23	28	43	37	30	28	28	19	21	25	32	35	39	34	45	50	44	56	47	37	47	53	64	64	84	96	101	97	118	124	139	157	171
Short-Term Debt	–	–	–	–	–	–	–	–	–	1.4	1.5	1.6	1.7	1.7	1.7	1.5	2.1	2.4	2.6	3.2	3.4	3.3	3.3	3.3	3.3	3.5	2.2	2.3	2.3	2.3	2.1	2.0	2.0	2.3	2.5	2.7	3.0	3.2	4.0
Accounts Payable	0.2	–	–	–	1.2	2.8	0.6	4.7	11	6.9	9.3	6.4	5.7	4.3	2.4	3.9	0.5	2.8	4.2	1.6	1.9	3.4	2.5	1.5	7.9	1.4	0.6	1.0	8.2	5.6	7.4	8.3	2.0	2.0	9.0	6.2	2.0	24	12
Long-Term Debt	–	–	–	–	–	–	0.0	0.0	–	2.2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	54	54	–	–	-90	205	342	319	279	307	275	252	225	206	250	359	312	271	236	214	185	166	153	384	396	390	412	405	439	432	435	437	438	457	495	535	568	606	654
Retained Earnings	-26	–	–	–	-91	-107	-127	-152	-194	-260	-297	-324	-356	-383	-420	-464	-517	-567	-609	-639	-675	-701	-721	-496	-492	-504	-489	-503	-478	-496	-500	-512	-521	-513	-495	-476	-462	-440	-414
Shares Outstanding	–	32	32	32	32	47	18	48	48	52	54	55	55	55	58	66	68	68	68	69	69	69	69	71	71	70	72	70	73	71	71	72	72	76	78	78	79	82	83

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings